Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal Stem Cells and Their Secretions at Palm Beach Anti-Aging Summit Tomorrow at Mar-a-Lago

Share Article

Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal Stem Cells and Their Secretions at Palm Beach Anti-Aging Summit Tomorrow, October 8th, at Mar-a-Lago from 3:50 pm to 4:30 pm.

Picture of Neil H. Riordan PhD

Neil H. Riordan, PhD

Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal Stem Cells and Their Secretions at Palm Beach Anti-Aging Summit Tomorrow, October 8th, at Mar-a-Lago from 3:50 pm to 4:30 pm.

Dr. Riordan is one of the early pioneers and leading experts of applied adult stem cell therapy.

He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute of Regenerative Orthopedics in Southlake, Texas; Founder and Chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama; founder of Stem Cell Institute (SCI) in Panama City, Panama; and founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time.

Dr. Riordan has published over 60 scientific articles in international peer-reviewed journals and authored two book chapters on the use of non-controversial stem cells from placenta and umbilical cord. In the stem cell arena, he and his colleagues have published more than 20 articles on Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis, Duchenne Muscular Dystrophy, Autism, and Charcot Marie Tooth Syndrome. In 2007, Dr. Riordan’s research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery, his team was honored with the “Medical Article of the Year Award” from Biomed Central. Other notable journals in which Dr. Riordan has published articles include the British Journal of Cancer, Cellular Immunology, Journal of Immunotherapy, and Translational Medicine.

Dr. Riordan is an accomplished inventor; listed on more the 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin C’s preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.

Under the umbrella of Medistem Panama subsidiary Translational Biosciences, Medistem Panama and Stem Cell Institute are currently conducting IRB-approved clinical trials in Panama for autism, multiple sclerosis, rheumatoid arthritis and osteoarthritis and spinal cord injury using human umbilical cord-derived mesenchymal stem cells.

This event is sold out.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the BioMAC (Pat. Pend.) bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*Amniotic Therapies Inc. produces AlphaGEMS and AlphaPATCH products from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit:

801 E. Southlake Blvd.
Southlake, Texas

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Stem Cell Institute Panama

Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: autism, cerebral palsy, multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.

In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for autism, multiple sclerosis, osteoarthritis, rheumatoid arthritis, and spinal cord injury using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2016, Translation Biosciences plans to expand its clinical trial portfolio to include heart disease and cerebral palsy.

For more information on stem cell therapy:

Stem Cell Institute Website:

Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jay D Lenner Jr
Visit website